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Abstract. An increase in skin rashes or atopic dermatitis has 
been observed in individuals working with vanadium. However, 
to the best of our knowledge no in vivo or in vitro studies have 
evaluated the effect of exposure to vanadium in dermal fibro-
blasts. Cells viability and proliferation were assessed by WST-1 
assay, cells were treated with increasing concentrations of V2O5 
(1, 10 and 100 nM). CXCL8 and CXCL11 concentrations were 
measured in the supernatants using an ELISA assay. V2O5 was 
not observed as having a significant effect on dermal fibroblast's 
viability and proliferation. However, it was revealed that V2O5 
was able to induce the secretion of CXCL8 and CXCL11 chemo-
kines into dermal fibroblasts. V2O5 synergistically increased the 
effect of interferon (IFN)γ on CXCL11 secretion. In addition, 
V2O5 synergistically increased the effect of the tumor necrosis 
factor α on CXCL8 secretion and abolished the inhibitory effect 
of IFNγ. V2O5 induction of CXCL8 and CXCL11 chemokines 
may lead to the appearance and perpetuation of an inflamma-
tory reaction into the dermal tissue. Further studies are required 
to evaluate dermal integrity and manifestations in subjects 
occupationally exposed, or living in polluted areas.
Introduction
Vanadium is a grey metal that exists in different states 
of oxidation (ranging from -1 to +5) of which vanadium 
pentoxide (V2O5) is the most usual form.
All vanadium compounds have been considered toxic. 
The exposure limit to V2O5 dust and fumes in workplace 
air (8 h work day/40 h work week) has been fixed by the 
Occupational Safety and Health Administration in 0.05 and 
0.1 mg/m3, respectively (1).
The National Institute for Occupational Safety and Health 
(NIOSH) sets to 35 mg/m3 the dose of vanadium exposure that 
may cause seriously health issues up to death (1).
Toxic effects of vanadium are reflected mainly on respira-
tory system, while the effect on the gastrointestinal system is 
less relevant because of the minimal gut absorption rate of the 
substance (2-4). Unfortunately, no sufficient data are available 
in order to determine the reference range of a subchronic or 
chronic inhaled dose.
Studies conducted on rat models showed the toxic effects 
(resulted from an oral, or inhaled, vanadium exposures) on 
serum parameters (5,6), liver (7), nervous (8) and other tissues 
development (9).
Vanadium workers (NIOSH 1983) showed an increased 
prevalence of skin rashes, such as atopic dermatitis.
Until now no in vivo, or in vitro, studies were carried out 
to evaluate the effect of exposure to vanadium in dermal 
fibroblasts.
Here, we evaluate the effect of V2O5 on viability and 
proliferation, and secretion of chemokine (C-X-C motif) 
ligand (CXCL)8, or CXCL11 [an interferon (IFN)γ dependent 
chemokine, of the same class of CXCL9, and CXCL10] in 
dermal human fibroblasts.
Materials and methods
Fibroblast cell cultures. We have obtained fibroblasts from 
derma of six patients who underwent an operation for thyroid 
nodular goiter (discard dermal material; all females, age range 
57-76 years, euthyroid, without other disorders or diseases, and 
not treated with any kind of drugs).
Involved subjects gave their informed consent and the study 
was approved by the University of Pisa (Pisa, Italy) Ethics 
Committee. Tissue explants were firstly minced and then 
placed in culture dishes, allowing the fibroblasts proliferation 
(as previously described) (10). Fibroblasts were propagated in 
199 medium [with 20% FBS (Gibco; Thermo Fisher Scientific, 
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Waltham, MA, USA), gentamycin (20 µg/ml), penicillin 
(100 U/ml)], in a 37˚C humidified incubator with 5% CO2; and 
maintained subsequently in a 199 medium with 10% FBS (and 
antibiotics) (11). The cells were all used at the 4th passage, and 
were tested for purity by immunocytochemistry (12).
Proliferation and viability. We have done the WST-1 
(Roche Diagnostics, Almere, The Netherlands) assay (that 
uses 3‑[4,5‑dimethylthiazol‑2‑yl]‑2,5‑diphenyltetrazolium 
bromide, in the MTT assay) to evaluate cell viability and 
proliferation (13-16).
Firstly fibroblasts were seeded in each well of 96-well 
plates at a concentration of 35,000 cells/ml (in a final volume 
of 100 µl).
Subsequently V2O5 effect on fibroblasts viability and 
proliferation was determined exposing cells for 24 h with 
increased concentrations of the compound (1, 10, 100 nM).
Fibroblasts were plated and treated with V2O5 or with its 
vehicle alone (for 24 h), performing all experiments in tripli-
cate for each cell preparation.
As the cell viability and proliferation WST-1 assay may 
have limitations on evaluating cellular proliferation (17), 
fibroblasts proliferation was determined also by cell number 
counting (13-16).
Chemokine secretion assay and ELISA. To perform the CXCL8 
and CXCL11 secretion assays, 30,000 cells/ml were seeded in 
96‑well plates, in a final volume of 100 µl per well, in growth 
medium, that was removed after 24 h. After cells were washed 
in PBS, and incubated (24 h) in phenol red and serum-free 
medium containing IFNγ (500, 1,000, 5,000, 10,000 IU/ml) 
and/or 10 ng/ml TNFα (all R&D Systems, Minneapolis, MN, 
USA), alone or in combination (10). The TNFα concentration 
to obtain the highest secretion was selected in preliminary 
experiments. After 1 day the supernatants were collected and 
then kept frozen at ‑20˚C (until chemokine assay).
We treated fibroblasts, for 24 h, with increasing concentra-
tions of V2O5 (1, 10, 100 nM), in presence/absence of IFNγ 
(1,000 IU/ml), and/or TNFα (10 ng/ml), in order to evaluate the 
effect of V2O5 on the chemokine secretion induced by IFNγ.
CXCL8 and CXCL11 concentrations were measured in the 
supernatants using the ELISA assay. The experiments were 
carried out three times, for each different cell preparation.
Chemokines levels were measured in culture supernatants, 
using commercially kits (R&D Systems). The mean minimum 
detectable dose was 2.7 pg/ml for CXCL8 and 3.2 pg/ml for 
CXCL11; the intra‑ and inter‑assay coefficients of variation 
were 3.5 and 6.5% for CXCL8, 4.7 and 8.5% for CXCL11. 
Quality control pools of low, normal, or high concentration for 
all parameters were included in each assay.
Statistical analysis. For normally distributed variables 
values are given in text as mean (±SD), or mean (±SEM) in 
figures, otherwise as median [and interquartile range]. Mean 
group values are compared by one-way analysis of variance 
(ANOVA) for variables normally distributed, or with the 
Kruskal-Wallis test, or Mann-Whitney U test. Proportions 
are compared by the Chi-Square. We have used the 
Bonferroni-Dunn test for post hoc comparison of normally 
distributed variables.
Results
Cell proliferation of dermal fibroblasts. Cell counting shows 
that V2O5 (1, 10, 100 nM) does not change viability or prolifera-
tion of dermal fibroblasts (Fig. 1). The results of WST-1 assay in 
dermal fibroblasts with V2O5 (1, 10, 100 nM) confirmed the cell 
counting data: with V2O5 1 nM it was 99% with respect to the 
control; with V2O5 10 nM it was 97% with respect to the control; 
and with V2O5 100 nM it was 98% with respect to the control.
Fibroblast secretion of CXCL8. In basal conditions, the secre-
tion of CXCL8 (range, 51-213 pg/ml) was measured in all 
preparations of cultured dermal fibroblasts (Fig. 2).
CXCL8 secretion increased in a dose-dependent manner 
using different concentrations of TNFα (1, 5, 10 ng/ml), with 
the highest response reached with 10 ng/ml TNFα (basal 
156±46 pg/ml vs. TNFα 1154±321 pg/ml; P<0.01) (Fig. 2).
The basal CXCL8 secretion was significantly inhibited by 
IFNγ in a dose-dependent manner (CXCL8: 84±37, 34±25, pg/ml; 
respectively, with IFNγ 500 or 1,000 IU/ml; ANOVA, P<0.05), 
while TNFα alone (10 ng/ml) significantly stimulated the 
CXCL8 secretion (P<0.01) (Fig. 3). Combining IFNγ with 
TNFα led to a significant reversal of the stimulating effect of 
TNFα (TNFα+IFNγ 661±176 pg/ml vs. TNFα 1154±321 pg/ml; 
P<0.05) (Fig. 3). However, the stimulating effect of TNFα on 
the secretion of CXCL8 was not completely reversed by IFNγ, 
because the concentration of this chemokine was still signifi-
cantly higher than in basal conditions (TNFα+IFNγ vs. basal; 
P<0.01).
When fibroblasts were treated with increased V2O5 
concentrations (1, 10, 100 nM) the CXCL8 release was 
dose-dependently stimulated (P<0.0001, by ANOVA) (Fig. 4).
When treating dermal fibroblasts with V2O5 (100 nM), 
together with IFNγ, CXCL8 release was not significantly 
changed with respect to the basal condition, and IFNγ 
suppressed the V2O5 stimulating effect, but it stills increased it 
compared to IFNγ alone (Fig. 5).
V2O5 (100 nM) plus TNFα elicited a synergistic effect on 
CXCL8 secretion (P<0.0001, by ANOVA), compared to TNFα 
alone (Fig. 6).
The CXCL8 release synergistically increased (P<0.0001, 
by ANOVA), when fibroblasts were treated with V2O5 
(100 nM) with the combination of IFNγ and TNFα, abolishing 
the inhibitory effect of IFNγ (Fig. 7).
Fibroblast secretion of CXCL11. CXCL11 release was 
inducted by IFNγ in a dose-dependent manner (CXCL11: 0, 
31±17, 87±35, 123±47, 187±52 pg/ml; respectively, with IFNγ 
0, 500, 1,000, 5,000, 10,000 IU/ml; ANOVA, P<0.001).
TNFα alone had no effect (chemokine remaining 
undetectable), while the combination of IFNγ and TNFα 
had a significant synergistic effect on the CXCL11 secre-
tion (CXCL11, 1724±252 vs. 87±35 pg/ml with IFNγ alone, 
ANOVA, P<0.0001).
When fibroblasts were treated with increased V2O5 
concentrations (1, 10, 100 nM) the CXCL11 release was 
dose-dependently stimulated (ANOVA, P<0.0001) (Fig. 8).
CXCL11 release was not significantly changed treating 
cells with V2O5 (100 nM), together with TNFα, with respect 
to V2O5 alone (data not shown).
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When treating fibroblasts with V2O5 (100 nM), plus IFNγ, 
CXCL11 release synergistically increased (P<0.0001, by 
ANOVA), compared to both IFN or V2O5 alone (Fig. 9).
CXCL11 release was synergistically increased (ANOVA, 
P<0.0001) when fibroblasts were treated with V2O5 (100 nM), 
together with IFNγ and TNFα stimulation, compared to 
IFNγ+TNFα (Fig. 10).
Discussion
Our results demonstrate that V2O5 stimulates the secretion of 
the CXCL8 chemokine, and of the IFNγ dependent chemokine 
CXCL11, in dermal fibroblasts, without altering their viability 
Figure 1. V2O5 treatment does not significantly change the proliferation of 
dermal fibroblasts (mean group values are compared using one‑way analysis 
of variance; the Bonferroni-Dunn test was used for post-hoc comparison; 
P>0.05, for all comparisons). V2O5, vanadium pentoxide.
Figure 2. CXCL8 secretion was measured in all cultured dermal fibroblasts 
preparations in basal conditions (control); its secretion increased signifi-
cantly and dose-dependently with different concentrations of TNFα (1, 5 
and 10 ng/ml) (the Bonferroni-Dunn test was used for post-hoc comparison). 
*P<0.05 vs. control. TNF, tumor necrosis factor.
Figure 5. Treatment of dermal fibroblasts with V2O5 (100 nM) abolished the 
inhibitory effect of IFNγ (the Bonferroni-Dunn test was used for post-hoc 
comparison; *P<0.05 vs. Control; °P<0.05 vs. IFN+V205). V2O5, vanadium 
pentoxide; IFN, interferon.
Figure 4. CXCL8 release was dose-dependently stimulated by treating 
dermal fibroblasts with V2O5 (1, 10 and 100 nM). *P<0.05 vs. control (the 
Bonferroni-Dunn test was used for post-hoc comparison). V2O5, vanadium 
pentoxide.
Figure 3. IFNγ (1,000 IU/ml) significantly inhibited the basal CXCL8 
secretion. The stimulating effect of TNFα was significantly reversed after 
the addition of IFNγ (the Bonferroni-Dunn test was used for post-hoc 
comparison; *P<0.05 vs. Control; °P<0.05 vs. TNF; §P<0.05 vs. IFN+TNF; 
$P<0.05 vs. IFN). IFN, interferon; TNF, tumor necrosis factor.
Figure 6. CXCL8 release was significantly increased by treating dermal 
fibroblasts with V2O5 (100 nM) and TNFα. *P<0.05 vs. the TNF group. V2O5, 
vanadium pentoxide; TNF, tumor necrosis factor.
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and proliferation. Moreover, our study confirms that IFNγ and 
TNFα stimulated in a different way, the secretion of CXCL8, 
or CXCL11, chemokines as expected (18). Interestingly, V2O5 
can synergize with IFNγ and TNFα, furtherly increasing 
CXCL11 secretion. In addition, V2O5 combined with TNFα, 
elicited a synergistic influence on CXCL8 chemokine produc-
tion, abolishing the inhibitory effect of IFNγ.
These results, on the whole, agreed with the view that V2O5 
is able to induce and perpetuate an inflammatory disorder in the 
dermal tissue inducing inflammatory chemokines secretion (13).
Our findings regarding TNFα, and IFNγ effect in fibro-
blasts are in line with the results of another study in a different 
type of cells. In fact, it has been recently investigated if CXCL8 
and CXCL10 chemokines secretion by normal human thyro-
cytes is dependent upon specific proinflammatory stimuli. 
CXCL8, but not CXCL10 (an IFNγ inducible chemokine, of 
the same class of CXCL11), was detected in basal conditions. 
The two chemokines showed differences in their response to 
proinflammatory cytokines.
Actually, IFNγ induced a significant CXCL10 secretion, 
not obtained with TNFα; whereas CXCL8 was secreted 
in response to TNFα, being instead inhibited by IFNγ. The 
combination of TNFα plus IFNγ synergistically increased 
the IFNγ-induced CXCL10 secretion, while reversed the 
TNFα-induced CXCL8 secretion (19).
IFNγ-inducible CXC chemokines can be produced by 
several types of normal mammalian cells, such as thyro-
cytes, fibroblasts, colon epithelial cells, islet cells, and 
others (10,13,14,19-25). However, these cells are not able to 
produce the CXC chemokines in basal condition, but only 
when stimulated by cytokines, such as IFNγ and TNFα, that 
are released in a T‑helper 1 (Th1) type inflammatory site, such 
as the thyroid at the beginning of Graves' disease, by Th1 acti-
vated lymphocytes. It has been suggested that this process can 
be involved in the initiation and the perpetuation of the inflam-
mation in several autoimmune diseases (10,13,14,19-25), and 
considering our results it can be applied to the thyroid, too.
Our findings about vanadium stimulation of chemokines 
agree with those of other studies conducted in different cell 
types. V2O5 exposure is a cause of occupational bronchitis; a 
study evaluated gene expression profiles in human lung fibro-
blasts (in cultures) after V2O5 exposure with the aim to identify 
genes that could be implicated in the bronchial inflammation, 
repair, and fibrosis in the pathogenesis of bronchitis. Among 
Figure 7. Treatment of dermal fibroblasts with V2O5 (100 nM) + IFNγ + TNFα 
stimulation significantly increased CXCL8 release (the Bonferroni‑Dunn 
test was used for post-hoc comparison; *P<0.05 vs. IFN+TNF+V2O5; $P<0.05 
vs. TNF; °P<0.05 vs. IFN+TNF). V2O5, vanadium pentoxide; TNF, tumor 
necrosis factor; IFN, interferon.
Figure 8. CXCL11 release was dose-dependently stimulated by treating 
dermal fibroblasts with V2O5 (1, 10 and 100 nM). *P<0.05 vs. the control (the 
Bonferroni-Dunn test was used for post-hoc comparison). V2O5, vanadium 
pentoxide.
Figure 10. CXCL11 release was significantly increased by treating dermal 
fibroblasts with V2O5 (100 nM) + IFNγ and TNFα *P<0.05 vs. the control 
group. ˚P<0.05 vs. the IFN+TNF group (the Bonferroni‑Dunn test was used 
for post-hoc comparison). V2O5, vanadium pentoxide; TNF, tumor necrosis 
factor; IFN, interferon.
Figure 9. When dermal fibroblasts were treated with V2O5 (100 nM) + IFNγ 
CXCL11 release was significantly increased *P<0.05 vs. the control group. 
$P<0.05 vs. the IFN group. ˚P<0.05 vs. the V205 group (the Bonferroni-Dunn 
test was used for post-hoc comparison). V2O5, vanadium pentoxide; IFN, 
interferon.
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the 10 genes overexpressed by V2O5, also CXCL8, CXCL9 and 
CXCL10 were induced (26).
Another study reports that fibroblasts have a role in the 
innate immune response to vanadium-induced oxidative stress 
through the synthesis of IFNβ and the activation of STAT-1 
that cause an increase of CXCL10 levels (27).
Interestingly vanadium can increase chemokine secretion in 
a dose range, from 1 to 100 nM. It could be observed that normal 
blood levels of vanadium are ranging from 0.45 to 18.4 nM, and 
that 100 nM is a dose that might mimick an abnormally high 
exposure (28). So we could hypothesize that the induction of an 
inflammatory reaction into the dermal tissue could predispose 
to the appearance of skin rashes, or atopic dermatitis.
In conclusion our study shows that V2O5 can induce 
CXCL8, and CXCL11 chemokines secretion into the dermal 
fibroblasts. Interestingly, V2O5 synergistically increased the 
effect of the IFNγ on CXCL11 secretion. Moreover, V2O5 
synergistically increased the effect of the TNFα on CXCL8 
secretion, abolishing the inhibitory effect of IFNγ. Overall 
CXCL8, and CXCL11 chemokines induction by V2O5 could 
lead to the appearance and perpetuation of an inflammatory 
reaction into the dermal tissue. Further studies are needed to 
evaluate dermal integrity, and manifestations in subjects occu-
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